What Is MPFF in Flavonoids by PureLife NUTRITION ?
MPFF (Micronized Purified Flavonoid Fraction) is a standardized, clinically tested mixture of natural citrus flavonoids (90% diosmin + 10% hesperidin and related flavones).
The “micronized” process reduces particle size, improving intestinal absorption and bioavailability — making it significantly more effective than non-micronized diosmin.
It is widely marketed under trade names such as Daflon®, Venalex®, Venosmine®, Detralex®, etc.
What Is Chronic Venous Disease (CVD)?
CVD refers to conditions in which venous blood return from the legs is impaired, leading to:
- Leg heaviness, pain, swelling, cramps
- Varicose veins
- Skin changes (hyperpigmentation, eczema)
- Venous ulcers (advanced stage)
Mechanism of Action: How MPFF Works in CVD
MPFF improves venous and lymphatic function on several levels:
| Target | Mechanism | Clinical Effect |
| Venous wall tone | Enhances smooth-muscle response to norepinephrine → tighter, more elastic veins | ↓ Venous distension, better venous return |
| Capillary permeability | Decreases plasma leakage & fragility | ↓ Edema & swelling |
| Lymphatic drainage | Increases frequency & amplitude of lymph vessel contractions | Better tissue fluid removal |
| Inflammation | Inhibits leukocyte adhesion to endothelium, reduces COX-2 and cytokines | ↓ Pain, heaviness, microvascular damage |
| Microcirculation | Improves oxygen delivery & flow | Better tissue health, reduced ulcer risk |
Clinical Benefits in Chronic Venous Disease
1. Reduction of Leg Symptoms
Multiple randomized, double-blind, placebo-controlled studies demonstrate that MPFF:
- Reduces leg heaviness, swelling, cramps, and pain
- Improves walking endurance and quality of life
📚 Evidence:
- Smith P.C., Angiology, 2005: MPFF significantly reduced leg pain, heaviness, and edema compared to placebo in patients with CVD stages C0–C3.
- Ramelet A., Int J Angiol, 2002: MPFF improved leg heaviness by ~45% and edema by ~30% after 2 months.
2. Reduction of Leg Edema (Swelling)
- MPFF improves capillary resistance and reduces venous stasis.
- Clinical trials show measurable reduction in ankle/leg circumference after 4–8 weeks of therapy.
- Objective microcirculatory measures (transcutaneous oxygen, lymphatic drainage) also improve.
📚 Evidence:
- Serra R. et al., Int J Mol Sci, 2020: 8-week MPFF led to significant edema and pain reduction vs placebo.
- Coleridge-Smith P., Int Angiol, 2005: MPFF reduced leg swelling and heaviness in mild-to-moderate CVD.
3. Improved Venous Ulcer Healing (Adjunct to Compression)
When added to compression therapy, MPFF accelerates ulcer healing, especially in large or chronic ulcers.
📚 Evidence:
- Coleridge-Smith et al., Int J Microcirc Clin Exp, 1997; Angiology, 2005:
Healing rates ↑ 32% vs control (p < 0.02), with greatest benefit for ulcers > 5 cm² or > 6 months old. - Meta-analysis (O’Donnell et al., J Vasc Surg, 2022): MPFF shortened ulcer healing time and increased healing probability vs compression alone.
4. Prevention of Disease Progression
- Long-term use improves venous tone, slows deterioration of valve competence, and prevents progression to skin changes or ulceration.
- Observational data suggest MPFF may delay need for surgery in symptomatic varicose veins.
📚 Evidence:
- Ramelet et al., Phlebology, 2012: Long-term MPFF use associated with improved quality-of-life scores and slower disease advancement.
5. Microcirculatory Protection
- MPFF reduces capillary rarefaction, leukocyte activation, and oxidative stress.
- It protects endothelial cells and preserves microvascular integrity.
📚 Evidence:
- Pascarella L. et al., Curr Vasc Pharmacol, 2014: MPFF reduced leukocyte adhesion and improved functional capillary density in venous hypertension models.
- Labropoulos N. et al., Vasc Endovasc Surg, 2016: Reported improved microvascular perfusion and reduced inflammation markers.
6. Adjunct After Venous Surgery or Ablation
- MPFF reduces postoperative pain, edema, and bruising.
- Enhances recovery and vein-wall healing after varicose vein surgery or sclerotherapy.
📚 Evidence:
- Caggiati et al., Phlebology, 2017: MPFF shortened recovery time and reduced postoperative swelling vs placebo.
Recommended Use in CVD
| Formulation | Typical Dose | Duration | Notes |
| MPFF (Daflon®, Venalex®, etc.) | 500 mg twice daily (or 1000 mg once daily) | 2–6 months (long-term safe) | Take with meals for best absorption |
| MPFF topical + systemic | As adjunct | For ulcers or post-surgery | Combine with compression & exercise |
Safety and Tolerability
- MPFF is very well tolerated — adverse events in < 2% of patients (mostly mild GI upset or headache).
- Safe for long-term use; no major hepatic, renal, or hematologic toxicity reported.
- No known drug interactions of clinical significance.
| Clinical Benefit | Strength of Evidence | Main Mechanism |
| ↓ Leg pain & heaviness | ⭐⭐⭐⭐ | Improves venous tone, reduces stasis |
| ↓ Leg edema/swelling | ⭐⭐⭐⭐ | Reduces capillary leakage |
| ↑ Ulcer healing (with compression) | ⭐⭐⭐⭐ | Improves microcirculation |
| ↓ Inflammation & oxidative stress | ⭐⭐⭐⭐ | Inhibits COX-2, leukocyte adhesion |
| ↑ Lymphatic drainage | ⭐⭐⭐ | Enhances lymph contractility |
| ↓ Post-surgical edema/pain | ⭐⭐⭐ | Venotonic & anti-inflammatory |
| Prevents CVD progression | ⭐⭐–⭐⭐⭐ | Endothelial protection |
In Short
MPFF (micronized diosmin + hesperidin) is one of the most evidence-based natural therapies in vascular medicine.
It:
- Improves symptoms of chronic venous insufficiency,
- Reduces swelling and heaviness
- Accelerates ulcer healing, and
- Supports microvascular and lymphatic health.
With an excellent safety record and strong clinical validation, MPFF is considered a first-line adjunct to compression therapy for CVD in many European vascular guidelines (e.g., ESVS 2022).
